Inhibrx Biosciences
- Market cap
- 1.37B
- P/E (TTM)i
- -10.51
- P/Bi
- -25.93
- EPSi
- -9.04
- Div yieldi
- 0.00%
- 52W posi
- 51%
Anonymous reader poll. Unscientific, not investment advice.
Inhibrx Biosciences ended the session at 93.36, down 0.05%. That leaves the company valued at approximately 1.37B, the #3022 most valuable US-listed company we track. Across 3 analysts the consensus rating is Buy, with an average price target of 266.67 (+186%). Against a 52-week band of 28.16-155.29, the shares are currently 51% of the way up.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 3% of the universe, above its 200-day average.
- Signal has read BUY for 2 months.
- Recent price momentum is +85.7% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has risen to 23.1% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 93.41
- Open
- 92.02
- Day range
- 90.66 - 96.71
- Avg price
- 94.08
- Volume
- 223.78K
- Turnover
- 21.05M
- Turnover ratei
- 2.61%
- Volume ratioi
- 0.94
- Amplitudei
- 6.48%
- 52-week rangei
- 28.16 - 155.29
Valuation
- P/Ei
- -10.33
- P/E (TTM)i
- -10.51
- P/Bi
- -25.93
- EPSi
- -9.04
- Book value / shi
- -3.60
- Net profit
- -133.05M
- Net assets
- -52.98M
Share structure
- Market cap
- 1.37B
- Float capi
- 801.86M
- Shares out
- 14.72M
- Float sharesi
- 8.59M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 2024-05-28
39.9% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+4.61M net over the window
Short interest
- Shares short
- 3.39M
- % of floati
- 23.06%
- Days to coveri
- 8.31
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Inhibrx Biosciences (INBX)?
Inhibrx Biosciences last traded at 93.36. The quote on this page refreshes every few seconds while US markets are open.
What is Inhibrx Biosciences's market cap?
About 1.37B.
What is the P/E ratio of Inhibrx Biosciences?
The trailing twelve-month P/E is -10.51. The Valuation tab shows it against the stock's own five-year range.
Does Inhibrx Biosciences pay a dividend?
Inhibrx Biosciences does not currently pay a regular dividend.
Is Inhibrx Biosciences a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 266.67, which implies 185.6% upside from the current price. This is not investment advice.
What is Inhibrx Biosciences's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Inhibrx Biosciences a B (Buy). Twelve-month momentum in the top 3% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.